KNBI.F Stock Overview
A biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kane Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.077 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.044 |
| Beta | 0.52 |
| 11 Month Change | -20.93% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -42.76% |
| 5 Year Change | -23.15% |
| Change since IPO | -87.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNBI.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 2.4% | 2.2% |
| 1Y | n/a | 16.2% | 31.7% |
Return vs Industry: Insufficient data to determine how KNBI.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KNBI.F performed against the US Market.
Price Volatility
| KNBI.F volatility | |
|---|---|
| KNBI.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNBI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KNBI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Marc Edwards | kanebiotech.com |
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Kane Biotech Inc. Fundamentals Summary
| KNBI.F fundamental statistics | |
|---|---|
| Market cap | US$10.82m |
| Earnings (TTM) | -US$3.92m |
| Revenue (TTM) | US$541.67k |
20.0x
P/S Ratio-2.8x
P/E RatioIs KNBI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNBI.F income statement (TTM) | |
|---|---|
| Revenue | CA$757.11k |
| Cost of Revenue | CA$298.78k |
| Gross Profit | CA$458.34k |
| Other Expenses | CA$5.93m |
| Earnings | -CA$5.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 60.54% |
| Net Profit Margin | -723.31% |
| Debt/Equity Ratio | -203.1% |
How did KNBI.F perform over the long term?
See historical performance and comparison